{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:33:26Z","timestamp":1791923606601,"version":"4.3.4"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40259-025-00741-1","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:51:00Z","timestamp":1758617460000},"page":"815-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis"],"prefix":"10.1007","volume":"39","author":[{"given":"Silvia","family":"Susin-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Munteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8735-6119","authenticated-orcid":false,"given":"Pablo","family":"Villoslada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E.","family":"Martinez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"741_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","volume":"76","author":"P Olejnik","year":"2024","unstructured":"Olejnik P, Roszkowska Z, Adamus S, Kasare\u0142\u0142o K. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects. Pharmacol Rep. 2024;76:926\u201343.","journal-title":"Pharmacol Rep"},{"key":"741_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(10)70103-4","volume":"9","author":"CH Polman","year":"2010","unstructured":"Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9:740\u201350.","journal-title":"Lancet Neurol"},{"key":"741_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","volume":"158","author":"V Brinkmann","year":"2009","unstructured":"Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173\u201382.","journal-title":"Br J Pharmacol"},{"key":"741_CR4","doi-asserted-by":"crossref","unstructured":"Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;2013:CD002127.","DOI":"10.1002\/14651858.CD002127.pub3"},{"key":"741_CR5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"H-P Hartung","year":"2002","unstructured":"Hartung H-P, Gonsette R, K\u00f6nig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018\u201325.","journal-title":"Lancet"},{"key":"741_CR6","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95:e1999-2008.","journal-title":"Neurology"},{"key":"741_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676\u201388.","journal-title":"N Engl J Med"},{"key":"741_CR8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"741_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4049\/jimmunol.1601358","volume":"198","author":"A Shirani","year":"2017","unstructured":"Shirani A, St\u00fcve O. Natalizumab for multiple sclerosis: a case in point for the impact of translational neuroimmunology. J Immunol. 2017;198:1381\u20136.","journal-title":"J Immunol"},{"key":"741_CR10","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1212\/WNL.0000000000000361","volume":"82","author":"J Romme Christensen","year":"2014","unstructured":"Romme Christensen J, Ratzer R, B\u00f6rnsen L, Lyksborg M, Garde E, Dyrby TB, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014;82:1499\u2013507.","journal-title":"Neurology"},{"key":"741_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756285615615257","volume":"9","author":"F Sellebjerg","year":"2016","unstructured":"Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9:31\u201343.","journal-title":"Ther Adv Neurol Disord"},{"key":"741_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/1352458511428465","volume":"18","author":"F von Glehn","year":"2012","unstructured":"von Glehn F, Farias AS, de Oliveira ACP, Damasceno A, Longhini ALF, Oliveira EC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012;18:1038\u201341.","journal-title":"Mult Scler"},{"key":"741_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1177\/1352458512463483","volume":"19","author":"A Harrer","year":"2013","unstructured":"Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler J. 2013;19:1209\u201312.","journal-title":"Mult Scler J"},{"key":"741_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med"},{"key":"741_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391\u2013403.","journal-title":"Neurology"},{"key":"741_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405\u201315.","journal-title":"Lancet Neurol"},{"key":"741_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:885\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"741_CR18","doi-asserted-by":"publisher","first-page":"117957352211354","DOI":"10.1177\/11795735221135485","volume":"14","author":"J Perneczky","year":"2022","unstructured":"Perneczky J, Sellner J. Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience. J Cent Nerv Syst Dis. 2022;14:11795735221135484.","journal-title":"J Cent Nerv Syst Dis"},{"key":"741_CR19","first-page":"392","volume":"95","author":"AA Toorop","year":"2024","unstructured":"Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, et al. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiatry. 2024;95:392\u2013400.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"741_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40120-024-00647-0","volume":"13","author":"H Wiendl","year":"2024","unstructured":"Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, et al. Patient preference for subcutaneous versus intravenous administration with every-6-week natalizumab (Tysabri\u00ae) dosing: NOVA phase IIIb extension study (part 2). Neurol Ther. 2024;13:1385\u2013401.","journal-title":"Neurol Ther"},{"key":"741_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21:608\u201319.","journal-title":"Lancet Neurol"},{"key":"741_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","volume":"82","author":"RJ Fox","year":"2014","unstructured":"Fox RJ, Cree BAC, De S\u00e8ze J, Gold R, Hartung H-P, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82:1491\u20138.","journal-title":"Neurology"},{"key":"741_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamaneurol.2022.5007","volume":"80","author":"B Hemmer","year":"2023","unstructured":"Hemmer B, Wiendl H, Roth K, Wessels H, H\u00f6fler J, Hornuss C, et al. Efficacy and safety of proposed biosimilar Natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the antelope phase 3 randomized clinical trial. JAMA Neurol. 2023;80:298\u2013307.","journal-title":"JAMA Neurol"},{"key":"741_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/14712598.2023.2290530","volume":"23","author":"H Wessels","year":"2023","unstructured":"Wessels H, von Richter O, Velinova M, H\u00f6fler J, Chamberlain P, Kromminga A, et al. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial. Expert Opin Biol Ther. 2023;23:1287\u201397.","journal-title":"Expert Opin Biol Ther"},{"key":"741_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40259-024-00671-4","volume":"38","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Roth K, H\u00f6fler J, Vitzithum K, Derlacz R, von Richter O, et al. Introducing the biosimilar paradigm to neurology: the totality of evidence for the first biosimilar natalizumab. BioDrugs. 2024;38:755\u201367.","journal-title":"BioDrugs"},{"key":"741_CR26","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819\u201328.","journal-title":"Lancet"},{"key":"741_CR27","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829\u201339.","journal-title":"Lancet"},{"key":"741_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol. 2017;74:961\u20139.","journal-title":"JAMA Neurol"},{"key":"741_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000360","volume":"4","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"741_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1212\/WNL.0000000000004381","volume":"89","author":"H Wiendl","year":"2017","unstructured":"Wiendl H, Bourdette D, Ciccarelli O. Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? Neurology. 2017;89:1098\u2013100.","journal-title":"Neurology"},{"key":"741_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000194","volume":"3","author":"S De Mercanti","year":"2016","unstructured":"De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflammation. 2016;3:e194.","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"key":"741_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/imm.12696","volume":"150","author":"S von Kutzleben","year":"2017","unstructured":"von Kutzleben S, Pryce G, Giovannoni G, Baker D. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology. 2017;150:444\u201355.","journal-title":"Immunology"},{"key":"741_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683\u2013747.","journal-title":"Annu Rev Immunol"},{"key":"741_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"741_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Br\u00fcck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707\u201317.","journal-title":"Ann Neurol"},{"issue":"9","key":"741_CR36","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.4049\/jimmunol.163.9.5133","volume":"163","author":"SE Baranzini","year":"1999","unstructured":"Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol. 1999;163(9):5133\u201344.","journal-title":"J Immunol"},{"issue":"3","key":"741_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PAJ, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395\u2013400.","journal-title":"Ann Neurol"},{"key":"741_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296\u2013301.","journal-title":"Science"},{"key":"741_CR39","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/brain\/awae244","volume":"148","author":"T Schneider-Hohendorf","year":"2025","unstructured":"Schneider-Hohendorf T, W\u00fcnsch C, Falk S, Raposo C, Rubelt F, Mirebrahim H, et al. Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain. 2025;148:933\u201340.","journal-title":"Brain"},{"key":"741_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/brain\/awy301","volume":"142","author":"MR von Essen","year":"2019","unstructured":"von Essen MR, Ammitzb\u00f8ll C, Hansen RH, Petersen ERS, McWilliam O, Marquart HV, et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2019;142:120\u201332.","journal-title":"Brain"},{"key":"741_CR41","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460\u201371.","journal-title":"Ann Neurol"},{"key":"741_CR42","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bj\u00f6rck A, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79:950\u20138.","journal-title":"Ann Neurol"},{"key":"741_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al. Comparative effectiveness of Rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75:320\u20137.","journal-title":"JAMA Neurol"},{"key":"741_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler J. 2023;29:221\u201335.","journal-title":"Mult Scler J"},{"key":"741_CR45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/1352458518757930","volume":"24","author":"F Piehl","year":"2018","unstructured":"Piehl F, Hillert J. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - yes. Mult Scler J. 2018;24:1157\u20139.","journal-title":"Mult Scler J"},{"key":"741_CR46","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, O\u2019Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet Lond Engl. 2011;378:1779\u201387.","journal-title":"Lancet Lond Engl."},{"key":"741_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"key":"741_CR48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320.","journal-title":"N Engl J Med"},{"key":"741_CR49","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357.","journal-title":"N Engl J Med"},{"key":"741_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjh.14447","volume":"176","author":"JP Sharman","year":"2017","unstructured":"Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol. 2017;176:412\u201320.","journal-title":"Br J Haematol"},{"key":"741_CR51","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S, et al. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022;387:704\u201314.","journal-title":"N Engl J Med"},{"key":"741_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jim.2017.03.014","volume":"445","author":"J Dock","year":"2017","unstructured":"Dock J, Hultin L, Hultin P, Elliot J, Yang OO, Anton PA, et al. Human immune compartment comparisons: optimization of proliferative assays for blood and gut T lymphocytes. J Immunol Methods. 2017;445:77\u201387.","journal-title":"J Immunol Methods"},{"key":"741_CR53","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova EG, Koenen HJPM, Borgman KJE, ten Berge IJ, Joosten I, Hilbrands LB. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013;13:1503\u201311.","journal-title":"Am J Transplant"},{"key":"741_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83:13\u201326.","journal-title":"Ann Neurol"},{"key":"741_CR55","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/j.clinph.2019.12.042","volume":"131","author":"T Derfuss","year":"2020","unstructured":"Derfuss T, Weber M, Hughes R, Eggebrecht J, Wang Q, Sauter A, et al. P36 serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clin Neurophysiol. 2020;131:e196.","journal-title":"Clin Neurophysiol"},{"key":"741_CR56","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024;271:1515\u201335.","journal-title":"J Neurol"},{"key":"741_CR57","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","volume":"28","author":"SL Hauser","year":"2022","unstructured":"Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler J. 2022;28:1576\u201390.","journal-title":"Mult Scler J"},{"key":"741_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184\u201391.","journal-title":"JAMA Neurol"},{"key":"741_CR59","doi-asserted-by":"publisher","unstructured":"Savelieva, Kahn J, Bagger M, Meier D, Tomic D, Leppert D, et al. Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies. [Internet]. Paris, France; 2017. https:\/\/doi.org\/10.1177\/1352458517731285","DOI":"10.1177\/1352458517731285"},{"key":"741_CR60","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/brain\/awae409","volume":"148","author":"G Androdias","year":"2025","unstructured":"Androdias G, L\u00fcnemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, et al. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain J Neurol. 2025;148:1459\u201378.","journal-title":"Brain J Neurol"},{"key":"741_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101468","volume":"37","author":"A Juto","year":"2020","unstructured":"Juto A, Fink K, Al Nimer F, Piehl F. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord. 2020;37:101468.","journal-title":"Mult Scler Relat Disord"},{"key":"741_CR62","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200152","volume":"10","author":"R Claverie","year":"2023","unstructured":"Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P, et al. Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing? Neurol Neuroimmunol Neuroinflamm. 2023;10:e200152.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"741_CR63","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200056","volume":"10","author":"C Starvaggi Cucuzza","year":"2023","unstructured":"Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, et al. Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200056.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"741_CR64","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","volume":"81","author":"G Jouvenot","year":"2024","unstructured":"Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, et al. High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurol. 2024;81:490\u20138.","journal-title":"JAMA Neurol"},{"key":"741_CR65","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1073\/pnas.93.6.2499","volume":"93","author":"K Gerritse","year":"1996","unstructured":"Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1996;93:2499\u2013504.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"741_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar6584","volume":"11","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci Transl Med. 2019;11:eaar6584.","journal-title":"Sci Transl Med"},{"key":"741_CR67","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.4049\/jimmunol.177.6.4196","volume":"177","author":"A Karni","year":"2006","unstructured":"Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006;177:4196\u2013202.","journal-title":"J Immunol"},{"key":"741_CR68","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3389\/fimmu.2017.01791","volume":"8","author":"SABM Aarts","year":"2017","unstructured":"Aarts SABM, Seijkens TTP, van Dorst KJF, Dijkstra CD, Kooij G, Lutgens E. The CD40\u2013CD40L dyad in experimental autoimmune encephalomyelitis and multiple sclerosis. Front Immunol. 2017;8:1791.","journal-title":"Front Immunol"},{"key":"741_CR69","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, et al. Inhibition of CD40L with Frexalimab in multiple sclerosis. N Engl J Med. 2024;390:589\u2013600.","journal-title":"N Engl J Med"},{"key":"741_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.msard.2016.04.006","volume":"8","author":"J van Horssen","year":"2016","unstructured":"van Horssen J, van der Pol S, Nijland P, Amor S, Perron H. Human endogenous retrovirus W in brain lesions: rationale for targeted therapy in multiple sclerosis. Mult Scler Relat Disord. 2016;8:11\u20138.","journal-title":"Mult Scler Relat Disord"},{"key":"741_CR71","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ana.23970","volume":"74","author":"D Kremer","year":"2013","unstructured":"Kremer D, Schichel T, F\u00f6rster M, Tzekova N, Bernard C, van der Valk P, et al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol. 2013;74:721\u201332.","journal-title":"Ann Neurol"},{"key":"741_CR72","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/13524585211024997","volume":"28","author":"H-P Hartung","year":"2022","unstructured":"Hartung H-P, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, et al. Efficacy and safety of temelimab in multiple sclerosis: results of a randomized phase 2b and extension study. Mult Scler. 2022;28:429\u201340.","journal-title":"Mult Scler"},{"key":"741_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956907","volume":"13","author":"T Chitnis","year":"2022","unstructured":"Chitnis T, Kaskow BJ, Case J, Hanus K, Li Z, Varghese JF, et al. Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects. Front Immunol. 2022;13:956907.","journal-title":"Front Immunol"},{"key":"741_CR74","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","volume":"18","author":"D Cadavid","year":"2019","unstructured":"Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovi\u0107 J, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18:845\u201356.","journal-title":"Lancet Neurol"},{"key":"741_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106185","volume":"93","author":"O Aktas","year":"2025","unstructured":"Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, et al. Renewed: a follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis. Mult Scler Relat Disord. 2025;93:106185.","journal-title":"Mult Scler Relat Disord"},{"key":"741_CR76","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.4049\/jimmunol.0902238","volume":"185","author":"JF Martin","year":"2010","unstructured":"Martin JF, Perry JSA, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol. 2010;185:1311\u201320.","journal-title":"J Immunol"},{"key":"741_CR77","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/archneurol.2009.50","volume":"66","author":"B Bielekova","year":"2009","unstructured":"Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009;66:483\u20139.","journal-title":"Arch Neurol"},{"issue":"9","key":"741_CR78","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","volume":"7","author":"BM Segal","year":"2008","unstructured":"Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7(9):796\u2013804.","journal-title":"Lancet Neurol"},{"key":"741_CR79","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/mt.2012.12","volume":"20","author":"Y Yan","year":"2012","unstructured":"Yan Y, Ding X, Li K, Ciric B, Wu S, Xu H, et al. CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Mol Ther. 2012;20:1338\u201348.","journal-title":"Mol Ther"},{"key":"741_CR80","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","volume":"263","author":"E Havrdov\u00e1","year":"2016","unstructured":"Havrdov\u00e1 E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263:1287\u201395.","journal-title":"J Neurol"},{"issue":"6","key":"741_CR81","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1346-8138.17143","volume":"51","author":"S Tsiogkas","year":"2024","unstructured":"Tsiogkas S, Tsimourtou V, Chaidaki K, Dardiotis E, Roussaki-Schulze A, Bogdanos D, et al. Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: A case-based review. J Dermatol. 2024;51(6):844\u20138.","journal-title":"J Dermatol"},{"key":"741_CR82","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/archneur.62.10.1561","volume":"62","author":"JM Schwab","year":"2005","unstructured":"Schwab JM, Monnier PP, Schluesener HJ, Conrad S, Beschorner R, Chen L, et al. Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain. Arch Neurol. 2005;62:1561\u20138.","journal-title":"Arch Neurol"},{"key":"741_CR83","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.2321","volume":"17","author":"R Muramatsu","year":"2011","unstructured":"Muramatsu R, Kubo T, Mori M, Nakamura Y, Fujita Y, Akutsu T, et al. RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis. Nat Med. 2011;17:488\u201394.","journal-title":"Nat Med"},{"key":"741_CR84","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.26503","volume":"93","author":"HV Kalluri","year":"2023","unstructured":"Kalluri HV, Rosebraugh MR, Misko TP, Ziemann A, Liu W, Cree BAC. Phase 1 evaluation of elezanumab (anti-repulsive guidance molecule A monoclonal antibody) in healthy and multiple sclerosis participants. Ann Neurol. 2023;93:285\u201396.","journal-title":"Ann Neurol"},{"key":"741_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27262","author":"BAC Cree","year":"2025","unstructured":"Cree BAC, Freedman MS, Gold M, Pfleeger K, Schwefel B, Wundes A, et al. Randomized, double-blind, placebo-controlled, multiple-dose studies to assess the safety and efficacy of Elezanumab when added to standard of care in relapsing and progressive forms of multiple sclerosis. Ann Neurol. 2025. https:\/\/doi.org\/10.1002\/ana.27262.","journal-title":"Ann Neurol"},{"key":"741_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ene.14105","volume":"27","author":"D Baker","year":"2020","unstructured":"Baker D, Pryce G, James LK, Schmierer K, Giovannoni G. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. Eur J Neurol. 2020;27:221\u20138.","journal-title":"Eur J Neurol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00741-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00741-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00741-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:47:41Z","timestamp":1761713261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00741-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00741-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"21 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was involved in the preparation of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SSC has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article. She has received travel expenses from Merck. EM has received travel support from Novartis, Merck, and BMS. PV holds stocks or stock options and has received consultancy fees, from\u00a0Bionure and Oculis, Spiral Therapeutics, Attune Neurociences, Adhera Health, Accure Therapeutics, QMENTA, Clarity Health technologies, Telara Pharma SL, Nimbus Therapeutics, and CLight. JEMR has participated as principal investigator in pharmaceutical company-sponsored clinical trials, including Novartis, Roche, Merck-Serono, Actelion, and Celgene, and received personal fees for consulting services and lectures from Novartis, Biogen-Idec, Sanofi, and Merck-Serono.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Available from the authors upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This review did not require ethics review or approval.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"There were no participants.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"There were no participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There was no code in this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SS: conceptualization, literature review, drawing illustrations, and drafting the article. EM: conceptualization and manuscript review. PV: conceptualization and manuscript review. JEM-R: conceptualization and manuscript review.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}